. Author manuscript; available in PMC: 2022 Mar 15.

Published in final edited form as: ACS Chem Neurosci. 2020 Oct 9;11(20):3233–3244. doi: 10.1021/acschemneuro.0c00364

Table 4.

Summary of the Properties of the Two Antibodies C-mab and G-mab^a

	crenezumab (C-mab)	gantenerumab (G-mab)
epitope	Aβ_12–28	Aβ_1–11
Aβ form	monomers, oligomers, and fibrils	monomers, oligomers, and fibrils
affinity	nM level	nM level
template	IGg4	IGg1
CDR-L1	²⁴RSSQSLVYSNGDTYLH³⁹	²⁴RASQSVSSSYLA³⁵
CDR-L2	⁵⁵KVSNRFS⁶¹	⁵¹GASSRAT⁵⁷
CDR-L3	⁹⁴SQSTHVPWT¹⁰²	⁹⁰LQIYNMPIT⁹⁸
CDR-H1	³¹SYGMS³⁵	³¹SYAMS³⁵
CDR-H2	⁵⁰SINSNGGSTYYPDSVKG⁶⁶	⁵⁰AINASGTRTYYADSVKG⁶⁶
CDR-H3	⁹⁹GDY¹⁰¹	⁹⁹GKGNTHKFYGYVRYFDV¹¹⁵

L1–L3, 1st–3rd CDR regions of LC; H1–H3, 1st–3rd CDR regions of HC.